Protein Sciences calls on Connecticut to buy its flu vaccine

Protein Sciences is calling on its home state to kickstart its entry into the flu vaccine sector by purchasing its shot. The Connecticut-based biotech won approval for its flu vaccine last year but it faces competition from GlaxoSmithKline ($GSK), Sanofi ($SNY) and the other established giants of the market. Protein Sciences' vaccine differs from these rivals because it is made using an insect cell-based production process. Article